Ira Bergman

Summary

Affiliation: Children's Hospital of Pittsburgh
Country: USA

Publications

  1. ncbi Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells
    Ira Bergman
    Departments of Pediatric, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Virology 316:337-47. 2003
  2. ncbi Preferential targeting of vesicular stomatitis virus to breast cancer cells
    Ira Bergman
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA
    Virology 330:24-33. 2004
  3. ncbi Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu
    Ira Bergman
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Int J Cancer 121:425-30. 2007
  4. ncbi Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line
    Yanhua Gao
    Department of Pediatrics, University of Pittsburgh School of Medicine, PA 15213, USA
    J Virol 80:8603-12. 2006
  5. ncbi Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2
    Matthias Miederer
    Departments of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6985-92. 2004

Research Grants

  1. Targeted Recombinant VSV Virus to Treat Breast Cancer
    Ira Bergman; Fiscal Year: 2007

Collaborators

Detail Information

Publications5

  1. ncbi Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells
    Ira Bergman
    Departments of Pediatric, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Virology 316:337-47. 2003
    ..2 x 10(5)/ml. This work demonstrates the ability to easily create, directly from plasmid components, an oncolytic replicating VSV with a restricted host cell range...
  2. ncbi Preferential targeting of vesicular stomatitis virus to breast cancer cells
    Ira Bergman
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA
    Virology 330:24-33. 2004
    ..Analysis of the protein composition of the rrVSV found low expression of the modified Sindbis gp on the virus...
  3. ncbi Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu
    Ira Bergman
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Int J Cancer 121:425-30. 2007
    ..These studies demonstrate that targeted rrVSV eliminated peritoneal implants of Her2/neu expressing tumor and elicited an anti-tumor T-cell immunologic response...
  4. ncbi Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line
    Yanhua Gao
    Department of Pediatrics, University of Pittsburgh School of Medicine, PA 15213, USA
    J Virol 80:8603-12. 2006
    ..The specificity for cells expressing the Her2/neu receptor was unchanged. These studies demonstrate that serial passage can be used to rapidly evolve a VSV genome encoding an improved chimeric glycoprotein...
  5. ncbi Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2
    Matthias Miederer
    Departments of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6985-92. 2004
    ..The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis...

Research Grants5

  1. Targeted Recombinant VSV Virus to Treat Breast Cancer
    Ira Bergman; Fiscal Year: 2007
    ..The proposal focuses on breast cancer but could be equally applied to many other cancers for which suitable cell surface targets exist. ..